103201-84-9

Basic information

• Product Name: (2S,4S)-4-Cyclohexyl-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester
• Synonyms: (2S,4S)-4-Cyclohexyl-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester
• CAS NO: 103201-84-9
• Molecular Weight: 331.412
• Mol File: 103201-84-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S,4S)-4-Cyclohexyl-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4S)-4-Cyclohexyl-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester(103201-84-9)
• EPA Substance Registry System: (2S,4S)-4-Cyclohexyl-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester(103201-84-9)

Safety Data

• Hazardous Substances Data: 103201-84-9(Hazardous Substances Data)

Upstream product

• 17342-08-4 (S)-Pyroglutaminol 
• 1521-51-3 rac-3-bromocyclohexene 
• 90657-55-9 trans-4-cyclohexyl-L-proline hydrochloride 
• 103201-80-5 (3R,6S)-6-Cyclohex-2-enyl-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one 
• 103201-81-6 ((2S,4S)-1-Benzyl-4-cyclohex-2-enyl-pyrrolidin-2-yl)-methanol 
• 1217546-92-3 (2R,SS)-2-phenyl-3-oxa-1-azabicyclo(3.3.0)octan-8-one 
• 103201-82-7 trans-4-cyclohexyl-L-prolinol 
• 501-53-1 benzyl chloroformate 
• 103201-83-8 (2S-trans)-1-[(benzyloxy)carbonyl]-4-cyclohexyl-2-pyrrolidinemethanol 

Downstream Products

• 103201-78-1 (2S,4S)-4-cyclohexylpyrrolidine-2-carboxylic acid 

Relevant articles and documents

Conversion of L-Pyroglutamic Acid to 4-Alkyl-Substituted L-Prolines. The Synthesis of trans-4-Cyclohexyl-L-proline

(S)-5-(Hydroxymethyl)-2-pyrrolidinone (3), prepared from L-pyroglutamic acid, was condensed with benzaldehyde to obtain the O,N-acetal 4 in excellent yield.Alkylation of 4 with 3-bromocyclohexene followed by reduction gave trans-4-cyclohexyl-L-prolinol (7) in good chemical yield with excellent stereoselectivity.Sequential N-protection, oxidation of the alcohol to the acid, and N-deprotection furnished trans-4-cyclohexyl-L-proline (1) in excellent yield and quality.Compound 1 serves as an intermediate for the preparation of ACE inhibitors including Fosenopril.